List All Acute Myeloid Leukemia (AML) Trials

Acute Myeloid Leukemia (AML)

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status Conditions Phase Study ID
Recruiting Acute Myeloid Leukemia Phase I 20132322

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

Pamela Becker, MD, PhD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Men or women > 18 years old
  • Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory to standard treatment, for which no standard therapy is available or the subject refuses standard therapy
  • Ability to take oral medications and willing to record daily adherence to investigational product
  • Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)
  • Active infection requiring intravenous (IV) antibiotics
  • Prior participation in an investigational study (procedure or device) within 21 days of study day 1
  • Major surgery within 28 days of study day 1
  • Anti-tumor therapy within 14 days of study day 1

Other exclusion criteria may apply.

Last Updated
December 02, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.